NCT00687505View on ClinicalTrials.gov

Safety Study of FP-1039 To Treat Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

May 31, 2011

Study Completion Date

June 30, 2011

Conditions
Advanced Cancer
Interventions
DRUG

FP-1039

Intravenous weekly administration

Trial Locations (2)

48201

Karmanos Cancer Institute, Detroit

78229

START (South Texas Accelerated Research Therapeutics), San Antonio

Sponsors

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

Five Prime Therapeutics, Inc.

INDUSTRY